Company Overview and News

3
3
3
4
Wheaton Precious Metals: Is It A Buy?

2018-08-30 seekingalpha
Wheaton Precious Metals (WPM) has reported its Q2 financial results, and it looks like a decent quarter, even with lower output from the San Dimas stream, which was restructured when the mine was sold. But does this make Wheaton's stock a buy here? There are still some issues that need to be addressed before I can recommend this stock.
WPM RGLD VALE ABX AG FNV RGL

3
3
6
Why the Earnings Surprise Streak Could Continue for VALE S.A. (VALE)

2018-08-13 zacks - 1
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider VALE S.A. (VALE - Free Report) . This company, which is in the Zacks Mining - Iron industry, shows potential for another earnings beat.
FOX VALE FOXA

3
3
24
Petrobras, Brazilian Stocks Recovering From Truckers' Strike

2018-08-07 seekingalpha
Petrobras, the centerpiece of "Lava Jato" and the company most exposed to Brazilian political interference, announced US$4.94B net profit in 1H18 (+226% YoY), its best results since 2011.
COP BP VALE XOM CVX TOT PBR YPF

9
5 Stocks Trading Near 52-Week High With More Upside in Store

2018-08-01 investorplace
A stock at a 52-week high level is perceived a winner. This level works as an indicator for many investors for buying or selling a stock.
COP VALE ALXN ADM NSIT

3
3
3
VALE / Vale S.A. 6-K (Current Report of Foreign Issuer)

2018-07-26 sec.gov
Table of Contents <
VALE

3

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to VALE / Vale S.A. on message board site Silicon Investor.

Valeant Pharmaceuticals (VRX) Valeant Pharmaceuticals (VRX) Valeant Pharmaceuticals (VRX) Valens GroworksCorp VGW Valens GroworksCorp VGW Valens GroworksCorp VGW
VALE VALE VALE Valence Technology- How low can it go? (VLNC) Valence Technology- How low can it go? (VLNC) Valence Technology- How low can it go? (VLNC)
Companhia Vale Do Rio Doce (RIO) Companhia Vale Do Rio Doce (RIO) Companhia Vale Do Rio Doce (RIO) VALENCE TECHNOLOGY (VLNC) VALENCE TECHNOLOGY (VLNC) VALENCE TECHNOLOGY (VLNC)
Valeant Pharmaceuticals (VRX) Valeant Pharmaceuticals (VRX) Valeant Pharmaceuticals (VRX) VLO: Valero Energy Corp. VLO: Valero Energy Corp. VLO: Valero Energy Corp.
valence technology valence technology valence technology Valentineu0027s Day Thread Valentineu0027s Day Thread Valentineu0027s Day Thread
CUSIP: 91912E105